Investors’ intense focus on cancer therapies has been a catalyst for biotech ETFs and that focus is expected to intensify in the near-term. With two major cancer conferences imminent, focused biotech ETFs, such as the BioShares Biotechnology Products Fund (NasdaqGM: BBP) and the BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC), could be on the receiving end of some positive catalysts. [Bet on new Breed Biotech ETFs]

Year-to-date, five of the 10 top-performing non-leveraged sector ETFs are biotech funds, including BBP, BBC, XBI and FBT.

S&P Capital IQ has overweight ratings on FBT and IBB. The research does not currently rate the other ETFs mentioned here.

iShares Nasdaq Biotechnology ETF

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.